

Image 1642



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-
CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER
OF PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON

03 FEBRUARY 2004

2/3/2004

DATE

Robert P. P. P.

NAME OF PERSON MAILING DOCUMENT

Attorney Docket No.: P50504C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Deen, *et al.* 03 February 2004
Serial No.: 10/066,895 Group Art Unit: 1642
Filed: 04 February 2002 Examiner: Larry Ronald Helms
For: Anti-RSV Human Monoclonal Antibodies

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE OF RESTRICTION REQUIREMENT UNDER
37 C.F.R. §1.143


Sir:

This paper is in response to the Office Action dated 08 January 2004, setting forth a thirty (30) day shortened statutory period for reply. This response is being filed within said period, and no fees are believed due. However, authorization is hereby given to deduct any fees required by this paper to Deposit Account No. 19-2570, should any fees be due.

Claims 1-17 are subject to a restriction requirement. Upon review of the Detailed Action provided by the Examiner, Applicants provisionally elect the subject matter of Group I. Claims 1-3 and 14-17, without traverse.

Applicants retain the right to file divisional applications on the non-elected subject matter, or any other claims supported by the instant specification, should the restriction requirement become final.

Respectfully submitted,



Elizabeth J. Hecht
Attorney for Applicants
Reg. No. 41,824

GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Telephone No.:(610) 270-4478
Facsimile No.:(610) 270-5090
N:\ERG\APPS\50504\CIrestreq.DOC